Foghorn Therapeutics (FHTX) Cash & Current Investments (2019 - 2026)

Foghorn Therapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $88.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 45.7% year-over-year to $88.9 million; the TTM figure through Mar 2026 stood at $88.9 million (up 45.7% YoY), while the FY2025 annual figure was $82.1 million, up 48.1% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $88.9 million, up from $82.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $213.6 million in Q1 2022, with the low at $50.6 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $73.8 million (2025), against an average of $82.4 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 221.52% in 2022, then sank 76.3% in 2023.
• Foghorn Therapeutics' Cash & Current Investments stood at $52.2 million in 2022, then jumped by 53.86% to $80.3 million in 2023, then tumbled by 30.97% to $55.5 million in 2024, then jumped by 48.1% to $82.1 million in 2025, then advanced by 8.26% to $88.9 million in 2026.
• Business Quant data shows FHTX's Cash & Current Investments at $88.9 million in Q1 2026, $82.1 million in Q4 2025, and $90.6 million in Q3 2025.